Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Syncona (SYNC) Share Price

Price 128.60p on 19-10-2026 at 18:05:10
Change -0.40p -0.31%
Buy 130.00p
Sell 128.60p
Last Trade: Sell 24,761.00 at 128.60p
Day's Volume: 369,214
Last Close: 128.60p
Open: 128.60p
ISIN: GG00B8P59C08
Day's Range 127.80p - 130.40p
52wk Range: 86.90p - 130.40p
Market Capitalisation: £782.15m
VWAP: 128.91624p
Shares in Issue: 608.20m

Syncona (SYNC) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 24,761 128.60p Uncrossing Trade
16:35:07 - 19-Oct-26
Buy* 10,000 130.00p SI Trade
16:21:12 - 19-Oct-26
Unknown* 10,000 130.00p OTC Trade
16:21:12 - 19-Oct-26
Sell* 564 128.7414p Ordinary
16:12:52 - 19-Oct-26
Buy* 510 130.00p Automatic Execution
16:00:51 - 19-Oct-26
Sell* 1 128.614p Ordinary
15:55:21 - 19-Oct-26
Sell* 52 128.60p Automatic Execution
15:44:31 - 19-Oct-26
Buy* 637 129.00p Automatic Execution
15:43:32 - 19-Oct-26
Buy* 1,011 129.00p Automatic Execution
15:43:32 - 19-Oct-26
Buy* 824 129.00p Automatic Execution
15:43:32 - 19-Oct-26
See more Syncona trades

Syncona (SYNC) Share Price History

Time period:
to
Date Open High Low Close Volume
19th Oct 2026 (Mon) 128.60 130.40 127.80 128.60 369,214
16th Oct 2026 (Fri) 125.00 130.00 125.00 129.00 405,858
15th Oct 2026 (Thu) 123.20 125.60 123.20 125.60 466,327
14th Oct 2026 (Wed) 123.40 124.20 123.00 124.00 94,568
13th Oct 2026 (Tue) 123.60 124.00 123.60 123.60 99,813
12th Oct 2026 (Mon) 123.00 124.00 123.00 124.00 90,989
9th Oct 2026 (Fri) 123.00 124.80 123.00 123.20 705,320
8th Oct 2026 (Thu) 122.40 122.80 122.40 122.80 216,874
7th Oct 2026 (Wed) 125.80 126.00 122.00 122.40 161,565
6th Oct 2026 (Tue) 124.00 124.20 122.00 122.00 295,572
5th Oct 2026 (Mon) 121.80 123.60 121.60 122.00 108,698
2nd Oct 2026 (Fri) 122.40 122.80 122.00 122.00 1,331,409
1st Oct 2026 (Thu) 123.60 123.60 122.00 122.00 232,280
30th Sep 2026 (Wed) 123.00 123.80 123.00 123.80 304,937
29th Sep 2026 (Tue) 123.00 124.00 122.20 122.40 312,263
28th Sep 2026 (Mon) 123.00 123.00 122.20 122.20 336,420
25th Sep 2026 (Fri) 118.40 124.00 118.00 122.00 5,496,911
24th Sep 2026 (Thu) 117.80 118.40 117.60 117.80 559,496
23rd Sep 2026 (Wed) 119.00 119.00 117.40 117.80 2,086,234
22nd Sep 2026 (Tue) 119.00 119.00 116.00 116.00 12,408,582
21st Sep 2026 (Mon) 114.20 120.20 114.20 117.40 35,993,657
See more Syncona price history

Syncona (SYNC) Regulatory News

Date Source Headline
15th Oct 2026 7:00 am RNS OMass raises $310 million in Series C financing
12th Oct 2026 7:00 am RNS Beacon presents Phase II/III data at AAO 2026
29th Sep 2026 7:00 am RNS-R SIML announces changes to leadership team
24th Sep 2026 12:00 pm RNS Holding(s) in Company
23rd Sep 2026 8:30 am RNS Holding(s) in Company
21st Sep 2026 7:00 am RNS Beacon delivers positive topline PII/III results
17th Sep 2026 4:30 pm RNS Holding(s) in Company
11th Sep 2026 3:15 pm RNS Holding(s) in Company
25th Aug 2026 5:15 pm RNS Holding(s) in Company
21st Aug 2026 8:00 am RNS Holding(s) in Company
See more Syncona regulatory news

Syncona (SYNC) Share News

EARNINGS AND TRADING: ZCCM names Joackim Bantubonse as new CFO

15th Oct 2026 17:31

(Alliance News) - The following is a round-up of earnings reports and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

WINNERS & LOSERS: US-China optimism supports miners; Syncona up

21st Sep 2026 10:32

(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Monday. Read More

IN BRIEF: Syncona says Beacon passes test in preventing vision loss

21st Sep 2026 08:58

Syncona Ltd - London-based life science investor - Portfolio holding Beacon Therapeutics Ltd's gene therapy laru-zova meets its primary endpoint in a phase II/III trial in treating the blinding condition X-linked retinitis pigmentosa. The endpoint, which was endorsed by the US Food & Drug Administration, was demonstrating statistically significant low luminesce visual acuity in patients at month 12, compared to a control group. XLRP is an inherited retinal disease that leads to progressive vision loss, moving from night blindness to being legally blind. Following the test results, Beacon plans a rolling biologics license application submission later this year. Read More

WINNERS & LOSERS: Vistry surges on UK government funding boost

25th Aug 2026 10:19

(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Tuesday. Read More

UK shareholder meetings calendar - next 7 days

11th Aug 2026 13:48

Read More

See more Syncona news
FTSE 100 Latest
Value10,764.69
Change-117.21

Login to your account

Forgot Password?

Not Registered